Mice with the P361R mutation in the lysosomal ceramidase, Asah1, exhibit a spinal muscular atrophy with progressive myoclonic epilepsy (SMA-PME)-like phenotype and may be a valuable tool to evaluate future therapies for SMA-PME. This evidence concerns the gene ASAH1 and progressive myoclonus epilepsy.